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INTRODUCTION
Anti Müllerian Hormone (AMH), also known as
Mullerian inhibiting substance, is a member of the
transforming growth factor  family of growth and
differentiation factors. AMH is known to have an
essential role in folliculogenesis. AMH inhibits the
growth of primordial follicles, and inhibits the
sensitivity of antral follicles to follicle-stimulating
hormone (FSH) during cyclical recruitment. Thus,
AMH is believed to play an important role in the
regulation of the ovarian follicular growth. In
addition, AMH is widely used as an ovarian
reserve marker.1,2 To date, the raise of AMH level
found in polycystic ovarian syndrome (PCOS) is
believed due to increased expression of the
promoter gene. In addition, its level increases up
to two to three times compared to normal women
worldwide.3,4 In addition, the more severe PCOS
phenotype one person has, the higher level of
plasma AMH is detected.4,5
PCOS is one of the diseases frequently found in
reproductive aged women. It affects both
endocrine and metabolic system. In fact, 46%
women with PCOS has shown association in the
development of metabolic syndrome in later life
(p<0.0001).6 A study in Korea surprisingly
demonstrated that young women with PCOS
(mean age of 26.5 years old) had a three-fold
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Objective: To evaluate whether Anti Müllerian Hormone (AMH) can
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Abstrak
Tujuan: Untuk mengevaluasi apakah Anti Müllerian Hormone
(AMH) dapat dijadikan prediktor untuk sindroma metabolikpada pasien Sindroma Ovarium Polikistik (SOPK).
Metode: Studi ini merupakan studi potong lintang yang dilakukan diKlinik Yasmin Rumah Sakit Dr. Cipto Mangunkusumo Jakarta pada
bulan Juni hingga Desember 2012. Empat puluh satu persen pasien
didiagnosis SOPK berdasarkan kriteria Rotterdam. Data sekunderdidapatkan dari rekam medis.
Hasil: Pada studi ini terdapat 22 pasien yang mengalami sindroma
metabolik. Nilai rerata kadar AMH pada pasien SOPK dengan sin-
droma metabolik ditemukan lebih tinggi dibandingkan dengan
pasien tanpa sindroma metabolik (10,726,23 ng/ml vs 7,974,50
ng/ml, p=0,12). Hasil penelitian ini juga menunjukkan bahwa AMH
berhubungan dengan HDL, trigliserida, dan resistensi insulin dengannilai r -0,29, 0,23, dan 0,21 (p < 0,05).
Kesimpulan: AMH dapat menjadi salah satu parameter untuk mem-
prediksi sindrom metabolik pada pasien SOPK.
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increased risk of developing metabolic syndrome
compared to normal population.7 However, due
to many panels of examinations should performed
to diagnose metabolic syndrome and not all
patients present with the same characteristics,
sometimes the diagnosis of metabolic syndrome
is disregarded.
Currently, the relationship between level of
AMH with the risk of cardiovascular event,
particularly metabolic syndrome, remains un-
known. Several studies suggested that the
disturbance in lipid profile in patient with PCOS
was not associated with body mass index.8
However, Skalba et al found that AMH was
significantly associated with total cholesterol, LDL
and HDL.9 Legro et al found that numerous PCOS
patients with metabolic syndrome were under
diagnosed, which may lead to inadequate
therapy.10 Therefore, a panel of examination that
can predict the risk of cardiovascular event in
PCOS is needed to be carried out, therefore
clinicians will be able give adequate treatment
to patients with PCOS.
METHOD
A cross sectional study design was used. The inclu-
sion criteria were women of reproductive age (15-
45 years) who met the diagnostic criteria for
PCOS based on Rotterdam 2003 in Yasmin Clinic,
Dr. Cipto Mangunkusumo General Hospital during
the period of June to December 2012 and agreed
to participating in the research. Patient who
consumed hormonal therapy or uses insulin-
sensitizing agents within three months before, and
had done ovarian drilling was being excluded. The
patient would be diagnosed as having PCOS
according to the Rotterdam consensus,11 which
were the finding of 2 out of the 3 following
criterias; oligo-and/or an ovulation, hyper andro-
genism, defined as hirsutism (Ferriman-Gallwey
score > 8), or minor signs including acne,
seboborrhea, and/or testosterone > 3 nmol/l
and/or androstenedione > 12 nmol/l, and criteria
for polycystic ovary by ultrasound examination
(minimum of 12 follicles with 2-9 mm diameter in
each ovary, and/or increasing ovarian volume with
a minimum size 10 mm3).
According to the American Heart Association,12
metabolic syndrome is diagnosed when someone
fulfill three among five diagnose criteria which are
blood pressure 130/85 mmHg, triglyceride 150
mg/dl, fasting blood glucose 100 mg/dl, HDL-C <
50 mg/dl, and waist circumference 80 cm (Asian
women).
Secondary data derived medical records were
used to obtain the data of the subjects including
AMH levels and all panels to diagnose metabolic
syndrome: blood pressure, triglyceride, HDL-C,
fasting blood glucose, and waist circumference.
Data were processed using Windows SPSS
version 11.0. Results were presented as mean
 SD. Relationship between each variable to
AMH level was analyzed with independent t-test,
p-value of < 0.05 would be considered statistically
significant.
RESULT
Using the Rotterdam criteria, 41 subjects were
diagnosed with PCOS. Among these patients,
twenty-two subjects were confirmed to have
metabolic syndrome while nineteen had normal
metabolic profile. Characteristics of the subjects in
the study are presented in Table 1.
Table 1. Baseline Characteristics of the Subjects
Metabolic syndrome (n=22) Non metabolic syndrome (n=19) p
Age (years) 30.14  2.88 31.11  3.43 0.33
BMI (kg/m2) 29.62  4.62 26.89  4.11 0.05
Waist circumference (cm) 91.80  9.72 87.00  7.19 0.08
Fasting blood Glucose (mg/dl) 102.45  29.45 89.16  6.64 0.06
HDL (mg/dl) 42.36  6.99 48.68  11.93 0.04
Triglyceride (mg/dl) 195.27  10.41 101.26  4.69 0.001
AMH (ng/ml) 10.72  6.23 7.97  4.50 0.12
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Mean age between patients who had metabolic
syndrome was younger than non metabolic
syndrome (30.14  2.88 vs 31.11  3.43).
Significant results in the metabolic syndrome
group were found in HDL level (42.36  6.99 vs
48.68  11.93, p = 0.04) and triglyceride (195.27 
10.41 vs 101.26  4.69, p < 0.001). Despite no
significant association was found, the level of
AMH was higher in the metabolic syndrome
group compared to the non - metabolic syndrome
group (10.72  6.23 vs 7.97  4.50, p = 0.12).
Independent t-test was performed to determine
the association of AMH between each of variable
of metabolic syndrome. Variables such as BMI,
waist circumference and fasting blood glucose
were not significantly associated with AMH,
whereas both HDL and triglyceride were
significantly associated with AMH (p < 0.05
[Table 2]).
Table 2. p-value of AMH as Predictor of each Variable of
Metabolic Syndrome
AMH p­value
BMI 0.05
Waist circumference 0.08
Fasting blood glucose 0.06
HDL 0.04
Triglyceride 0.01
DISCUSSION
We found no significant difference between
metabolic syndrome and non metabolic syndrome
in PCOS. Moreover, metabolic syndrome can be
seen as early as 30 years old. This finding is
consistent a previous study conducted Park which
demonstrated that young PCOS Korean women
with mean age of 26.5 years old were three times
at risk in developing metabolic syndrome in later
life.7
In this study, AMH was higher in the PCOS
group. This is consistent with previous studies.3,4
In addition, the metabolic syndrome population
had higher AMH levels compared to the non-
metabolic syndrome group. (10.72  6.23 vs 7.97
 4.50, respectively). Despite the non-sigfniciant
difference (p=0.12), 25% difference in clinical view
might be considered as a significant finding.
Numerous studies found that increased plasma
AMH level was significantly correlated with body
weight.13,14 However, we found no significant
association between BMI and AMH level (p=0.05),
which is consistent with a previous study con-
ducted by Skalba et al.13
To date, there is a new finding that AMH can
replaced one of the criteria diagnosis of Rotterdam,
such as polycystic ovarian morphology. Wiweko et
al found that AMH was proven to be significant
predictor of PCOS (cutoff value = 4.19ng/ml).4
More over, AMH can be used of predictor of
therapeutic response in PCOS.15 AMH was found to
have significant association with fasting insulin,
glucose, in women with or without PCOS. However,
this study did not demonstrate significant
association between fasting blood glucose with
level of AMH (p = 0.06).
It is well known that metabolic syndrome is
related to the development of cardiovascular risk
in later life. PCOS is not only disease of repro-
ductive system but also a disease of metabolic.
46% women with PCOS suffer from metabolic
syndrome.6,8 In addition, PCOS was associated
with the development of dyslipidemia in obese
women due to the increment of androgen level
which may lead to atherosclerosis.10,16 We found
that AMH was significantly associated with HDL
and triglyceride, which is in line with a previous
study conducted by Skalba et al. Based on these
findings, we suggest that AMH can be used as
potential predictor of metabolic syndrome in
PCOS. Our limitations include limited sample size.
Further studies are required to make the result
more useful, to treat PCOS more holistically.
CONCLUSIONS
AMH level is associated with two markers of
metabolic syndrome, triglyceride and HDL. This
study demonstrates that AMH might be used as a
potential predictor of metabolic syndrome in
PCOS. Thus clinician can be aware and treat it as
early as it can to prevent women with PCOS
from developing cardiovascular event.
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